Results: 60 patients randomized and 58 were analyzed (27-AP, 31-SoC, mean age 61.9y, mean MELD 11.7). Eighteen patients were included in the sub-study. Compared with SoC, median time to first LVP was not reached after 6 months in the AP group, meaning a significant reduction in LVP requirement for the AP patients (AP, median not reached ; SoC, 15 .0 days (95%CI 13.0, 22.0); HR: 0.13, p<0.001), and Chronic Liver Disease Questionnaire (HRQoL) score (p<0.05 between treatment arms). Improvements in nutritional parameters were observed for hand-grip strength (p=0.044) and body mass index (p<0.001) in the substudy. Compared with SoC, more AP patients reported adverse events (AEs; 96.3% vs. 77.4%, p=0.057) and serious AEs (85.2 vs. 45.2%, p=0.002). AEs consisted predominantly of acute kidney injury in the immediate post-operative period, and re-intervention for pump related issues, and were treatable in most cases. Survival was similar in AP and SoC.
Conclusions: The AP system is effective in reducing need for paracentesis and improving HRQoL in cirrhotic patients with RA. Although the frequency of SAEs (and by inference Introduction Accumulation of ascites is a common complication of cirrhosis and one of the leading reasons for hospital admission [1] . Approximately 60% of cirrhotic patients develop ascites within 10 years of diagnosis. Treatment of ascites includes restriction of dietary sodium and diuretics [2] . However, some patients develop diuretic-resistant or intractable ascites, because of diuretic-induced complications such as renal dysfunction, hyponatremia or hepatic encephalopathy (HE) [3, 4] .
Current guidelines for the treatment of refractory ascites (RA) are large volume paracentesis (LVP) [5] with albumin infusion to decrease the risk of paracentesis-induced circulatory dysfunction (PICD) [6] . Although LVP is considered safe, it requires patient hospital contact as often as weekly and is associated with poor quality of life and malnutrition, which together increase morbidity and mortality [7, 8] .
In selected patients with RA, a transjugular intrahepatic portosystemic shunt (TIPS) is a therapeutic alternative to repeated LVPs [9] . Unfortunately, TIPS is contraindicated in patients with marked pulmonary arterial hypertension, heart failure, advanced liver disease, significant hepatic encephalopathy, uncontrollable coagulopathy, and elevated right or left heart pressures [10] . Orthotopic liver transplantation is the only definitive treatment for RA, but availability is limited by organ availability, relatively low MELD scores that disadvantage RA patients on transplant waiting lists, and attendant costs [11] . Therefore, repeated LVP is the mainstay of treatment of RA.
The poor nutrition and decreased quality of life in RA patients treated with repeated LVPs, the Automated Low-Flow Ascites Pump System (alfapump ® system, Sequana Medical AG, Zurich, Switzerland ( Supplementary Figure 1) , was developed as an alternative to LVP. The alfapump is a fully implantable, programmable, and rechargeable pump system that automatically diverts ascitic fluid from the peritoneal cavity to the urinary bladder, allowing fluid removal by micturition. The system allows remote monitoring of fluid transport and tailored therapy dependant upon ascites production. The alfapump system is intended to provide an alternative treatment for RA, which may improve HRQoL and nutrition by reducing repeated LVPs in those patients who are not candidates for TIPS. PIONEER, a prospective, open label, uncontrolled study, demonstrated the safety of the alfapump system and a significant reduction in the need for paracentesis in patients with RA. The study, however, lacked a control group [12] .
The aim of this study was to perform a randomized and controlled study to evaluate the safety and efficacy of the alfapump system in cirrhotic patients with RA in comparison with LVP.
Materials and methods

Ethics
The study was approved by the ethics committees at all centers and registered on www.clinicaltrials.gov, #NCT01528410). Each patient gave written, informed consent in accordance with the principles of the Declaration of Helsinki of the World Medical Association [13] . All authors had access to the study data and reviewed and approved the final manuscript.
Definitions
Refractory ascites: Ascites that cannot be mobilized or early recurrence of which (i.e., after therapeutic paracentesis) that cannot be satisfactorily prevented by medical therapy [3] .
Acute Kidney Injury (AKI): All episodes of AKI (increase in serum creatinine of 0.3 mg/dL within 48 hours, or >50% from baseline within the prior 7 d [14, 15] , and renal insufficiency will be referred to as AKI.
Large Volume Paracentesis [16] : Removal of ≥5 L of ascitic fluid from the peritoneal cavity.
Paracentesis: Any therapeutic paracentesis including LVP but not including diagnostic paracentesis.
Study design and procedures
This prospective, multicenter, open-label, randomized, controlled study of patients with RA due to cirrhosis was performed at seven centers from five countries: United Kingdom, France, Austria, Spain and Italy (Supplemental Table 1 ). Randomised patients were followed for a nominal 180-day treatment phase, after which SoC patients were able to switch to the alfapump system study arm. An exploratory sub-study was performed on the first 18 patients enrolled at the Royal Free Hospital in London, to investigate the effects of the alfapump system on nutrition, hemodynamics and biomarkers of renal injury, after 90 d.
Paracentesis was carried out, when required, using study site standard protocols. Patients randomized to the AP arm received antibiotic prophylaxis (norfloxacin 400 mg/day or ciprofloxacin 750 mg/week) for study duration. Diuretic therapy was discontinued after implantation in all patients randomized to the AP arm, and re-started at investigator discretion if required. SoC group patients maintained their pre-study diuretic therapy regimen; changes to diuretic dosages were allowed at investigator discretion but were reduced or stopped in case of diuretic-related complications. Abstinence from alcohol and controlled salt intake were recommended for both groups throughout the study duration.
The alfapump was surgically inserted subcutaneously in the upper right quadrant of the abdomen, as described [12] . Perioperative antibiotics (ceftazidime 2 g and teicoplanin 400 mg pre-surgery and again 12 h post surgery) were recommended; deviations were allowed according to local practice. The alfapump system was activated the day after surgery. If necessary, pump parameters such as the targeted daily pump volume and the time of day during which the pump is active were adjusted during patient visits. Fluid transport by the alfapump was monitored remotely. Initial pump settings were estimated from the patient's paracentesis history and subsequently modified based on patient weight and volume of ascitic fluid present.
The schedule of visits was identical for both groups after the initial 7 d and included visits at Day 7, 14, 21, 30, 60, 90, and 180. AP patients were assessed daily during the period of hospitalization following alfapump implantation, whereas SoC patients were only seen during the first 7 days if necessary. For relevant comparison, safety is reported including and excluding the 7-day post-implant period. Albumin administration was at the discretion of the investigator and specifically indicated for (a) paracentesis, (b) spontaneous bacterial peritonitis and (c) episodes of acute kidney injury, and also for episodes of hyponatremia.
Patients enrolled in the sub-study underwent additional assessments at baseline, Day 30, and Day 90.
Eligibility
Males and non-pregnant females ≥18 years old with liver cirrhosis (based upon histological features, ultrasound, or clinical signs including ascites, hepatic encephalopathy, thrombocytopenia, and splenomegaly) and RA requiring periodic LVP (≥5 L) and albumin administration [4] were included (Supplementary Table 2 ). Subjects also needed to demonstrate willingness to comply with study procedures, the ability to operate the device, and centers were advised not to enroll subjects eligible for TIPS. Further exclusion criteria are listed in Supplimentary table 2 .
Primary endpoint was time to first LVP. Paracentesis was indicated when the patient complained of tense ascites and timing at investigator discresion. Secondary endpoints included overall paracentesis requirement, overall safety including renal injury and infections, a disease-specific health-related quality of life (HRQoL) instrument (chronic liver disease questionnaire (CLDQ)), and survival. Surgical, anesthetic and device-related complications in the treatment group were measured. Economic outcomes included number and cost of study visits, paracentesis visits, AE related visits and hospitalizations, over 6 months. In the sub-study, nutritional status including BMI, hand grip, mid-arm muscle circumference (MAMC), triceps skin fold thickness (TSF), and the Royal Free Hospital General Assessment (RFH-GA) [17] were measured. Additionally, hemodynamic markers and biomarkers of renal injury including cardiac index, systemic vascular resistance, plasma renin activity, kidney injury molecule-1 (KIM-1) and urinary neutrophil gelatinase-associated lipocalin (NGAL) were measured for sub-study patients.
Statistics and sample size
Patients were randomized to either the alfapump system group (treatment group AP) or LVP group (treatment group SoC) by a centralized, computer-generated method to achieve a 1:1 ratio. Over 6 months, 71% of AP patients are expected to require LVP [12] . Conservatively estimating 97% of SoC patients require LVP over 6 months equates to a hazard ratio (SoC:AP) of 2.83 [18] . Based on the assumption of proportional hazards, a log-rank test of equality of survival distributions, with a 5% two-sided significance level and 90% power requires 23 LVP events per group, requiring a sample size equivalent to 28 patients per group and 56 in total.
Analyses were carried out using SPSS Version 23.0, SAS Version 9.3 or higher, and R version 3.2.2. Descriptive analysis was performed for all primary and secondary variables.
Continuous variables were described with means, medians, standard deviation, 95% confidence interval, minimum and maximum values of each distribution, and interquartile range (IQR). Categorical variables were described using frequencies and percentage of patients in each category. Time to LVP and survival time were compared using Kaplan-Meier estimators and log-rank tests. Other parameters were compared using appropriate methods depending on the type.
HRQoL data were systematically collected for study participants at baseline, 1-, 2-, 3-and 6months' time points. The QoL scores were compared between the treatment arms using a non-parametric rank sum test, and to patients' own baseline levels using a sign rank test.
Economic analysis
A within-trial economic analysis was performed using a bottom-up approach [19] , and from the perspective of the National Health-Care System (NHS) in the UK. Only direct costs were included as follows: costs for alfapump implantation , costs of LVP, costs of typical management of ascites (laboratory tests, medications, scheduled visits), and costs related to AE treatment. For analysis of resource use and AEs costs: the AE category was determined using data on hospitalization requirement, elective vs. non-elective admission, diagnosis, and provided treatment; events were grouped for a single patient if they were reported during the same admission or out-patient visits, payment mechanism and costs were estimated for groups of events or individual events.
For cost estimates of treatment in each treatment arm, quantities of resource use were multiplied by their corresponding unit costs. Pharmaceuticals costs were estimated using British National Formulary [20] , Drugs and Pharmaceutical Electronic Market Information Tool [21] and National Health Services Drug Tariff for England and Wales [22] .Cost of physician/nurse visits was estimated using data from Personal Social Services Research Unit [23] and cost of hospital and out-patient specialist care was based on UK Departments' of Health NHS Reference cost [24] . All costs were presented using 2015/2016 British Pounds.
Inflation adjustments were made using Hospital & Community Health Services index.
For descriptive analyses for resource use and costs, median and interquartile range were used, Mann-Whitney U test was used for comparison between groups.
Sub-Study
The sub-study was designed to provide descriptive data and assess the effect of the alfapump on the measured parameters. A power calculation was not possible, as no prior data existed. A sample size of 18 patients (1:1 ratio AP versus SoC) was sufficient for the exploratory objectives of the sub-study.
The data were interpreted using an analysis of covariance using the baseline measure as the covariate. Plasma renin values were log10 transformed for analysis. Nutritional data were on an ordinal scale, whereby the three categories were ordered. These data were analyzed by the Cochran-Mantel-Haenszel procedure. The one and three-month data were stratified by their baseline category. The three ordered categories were assumed to be equally spaced.
Results
Baseline Characteristics and Patient Disposition
Between July 2012 and February 2015, 216 potential patients were pre-screened, and 81 patients signed informed consent. Most commonly unmet inclusion/exclusion criteria were; significantly decreased life expectancy or high anesthetic risk (comorbidity) (8.3%), unwilling to give consent (7.4%) no refractory ascites requiring LVP (6.5%), renal failure (6.5%), death before enrolment (5.6%), or advanced hepatocarcinoma (5.1%). Of the 81 consented patients, 60 patients met ultimate eligibility criteria and were randomized (screening and exclusion summary given in Supplemental Table 2 ) and constitute the intent-to-treat (ITT) population. Following randomization, 29 were allocated to the alfapump system treatment Baseline characteristics and patient demographics were well-balanced, with no significant differences between the two treatment groups (Table 1) Sub-study: The first 18 eligible patients at RFH were randomized to the sub-study and of these, 16 patients were included in the final analysis, eight in each group. One patient developed urinary retention before pump insertion and was withdrawn in the AP group, and one withdrew consent in the SoC group. Patient characteristics and demographic baseline data including the median age of patients, etiology of cirrhosis and the MELD scores were similar as shown in Table 1 .
Implant Procedure and Antibiotic Prophylaxis
In the AP group, 96.3% (26/27) patients received primary or secondary antibiotic prophylaxis for spontaneous bacterial peritonitis versus 80.6% (25/31) in the SoC group. LVP was required in 90% (28 patients) of the SoC group and 37% (10 patients) of the AP group. Of those in the AP group that required LVP, 4 patients accounted for 68% of all paracenteses, the causes of which are listed in Supplemental Table 3 . One AP group patient had the pump removed on Day 8 due to infection and required 7 post-explant LVPs.
Health-related quality of life (Chronic Liver Disease Questionnaire)
The disease-specific instrument, Chronic Liver Disease Questionnaire (CLDQ) was used to measure health-related quality of life (HRQoL) [25] . The Abdominal Symptoms and Activity scores improved significantly only in RA patients treated with alfapump (p<0.05 both when compared to baseline and between treatment arms). The average improvements in score after 3 months of treatment with alfapump were +1.25 and +0.80, respectively, on a 1-7 scale; notably, these improvements were sustained in AP group patients for months and substantially exceed the thresholds of clinical importance [26] . At the same time, no significant improvement in any HRQoL scores was observed in SoC group patients ( Figure 3 ).
Changes in QoL were not significantly different at 6 months.
Nutrition
Using the RFA-GA tool in the sub-study, improvement in nutritional status from baseline to Day 90 was seen in 4/8 (50%) patients in the AP group and none of the SoC group. In the 4 patients who improved in the AP group, 3/4 improved within 30 days and 1 improved after 90 days. In the AP group, 5/8 (63%) patients were "adequately nourished" at 90 days versus only 3/9 (33%) in the SoC group, and only 1 (13%) patient in the AP group did not complete 90 days versus 3 (33%) in the SoC group. Overall, there was a trend to improved nutritional status in the AP group compared with SoC (p=0.099 at Day 30 and p=0.090 at Day 90.
Nutritional parameters are shown in Table 2 . Compared with the SoC group, there were statistically significant improvements seen in body mass index (BMI), mid-arm muscle circumference, tricipital skin fold thickness, and hand grip strength in the AP group.
Health economic analysis
Median number of out-patient visits (3 [IQR 2, 9] Table 3 .
Of serious TEAEs, there were statistically more AP group patients with nervous system disorders (2 with hepatic encephalopathy, the others related to electrolyte abnormalities, alcohol withdrawal, and stroke; p=0.042), and renal and urinary disorders (p<0.001).
Procedural complications were observed in the AP patients and these are summarised in Table 3 .
Survival
There was no significant difference in overall survival (including off-treatment) between the AP and SoC groups (p=0.355) as shown in Supplementary Figure 2 . Six patients in the alfapump group and 4 patients in the SoC arm died during the 6-month study period. One death in the AP group occurred shortly after withdrawl from the study (still within 6 months) following recovery from pump explant for infection. Causes of death are consistent with advanced liver disease and are shown in Supplemental Table 4 . Supplemental Table 5 . Twenty-five patients in the AP group suffered treatment emergent infections with 23 fully recovering, 1 recovered with sequelae, and 1 deceased (sepsis), compared with 30 infections in the SoC group wherein 26 fully recovered, 3 were ongoing or outcome was unknown, and 1 deceased (SBP). Specifically, the incidences of spontaneous bacterial peritonitis and urinary tract infections were similar. The nature and frequency of patients with SAEs due to infection were similar in each group (p=0.883) as can be seen in Supplementary Table 5 and Table 3 (SAE by outcome section) .
Infection
TEAEs due to infection are shown in detail in
Circulatory dysfunction
Acute kidney injury
More than 50% of the AP group patients experienced SAEs related to the renal and urinary system. Except for 3 patients with hematuria and urethral stenosis, the others were due to AKI. Just over 41% of these AEs in the AP group (12/29) occurred in the first 7 days after implant and were transient, and of those 10/12 fully recovered and 2/12 improved (Supplemental Table 6 ). There were significantly more AKI events in the AP group than in the SoC group (29 vs. 11, respectively; p=0.007). If the first 7 post-operative days are excluded, there were similar numbers in each group (17 vs. 11, respectively; p=0.281, Table   3 ). One patient in the AP group with alcoholic liver disease and a history of hepatic encephalopathy died of end-stage liver disease and liver failure 52 days after implantation.
This was caused by septic shock and consequent AKI that occurred on the background of a severely infected diabetic foot requiring amputation.
Serum creatinine
There was no significant change from baseline in creatinine levels between or within groups at any time point. The means, medians and interquartile ranges (IQR) of changes in serum creatinine are shown in Supplementary Table 9 .
Serum albumin
The fall in albumin (g/L) over time was significantly greater in the AP group than SoC at Days 60, 90, and 180 (Supplementary Table 9 ). The AP group received significantly less total albumin after Day 0 over the course of the study than the SoC group (Supplementary Figure   5 ) and in the AP group, albumin was administered predominantly for renal insufficiency. In addition to infusion during LVP, albumin was administered in the SoC group for similar reasons.
Hyponatremia There were 7 hyponatremia-related AEs in 5 patients in the AP group, 3 of which required hospital admission and all occurred > 7 days after the implant. There were 3 hyponatremia AEs in 3 patients in the SoC group, one of which required hospitalisation and all occurred > 7 days after randomization. Each of these episodes was readily corrected with fluid restriction and/or volume resuscitation.
Hemodynamics, plasma renin activity, and inflammatory biomarkers including markers of kidney injury
In the sub-study, no significant changes were noted in cardiac index, mean arterial pressure, heart rate, stroke volume, or plasma B-type natriuretic peptide. A trend was noted suggesting an increase in both systemic vascular resistance (SVR, p=0.129) and plasma renin activity (p=0.144) at 3 months but not at 1 month. A statistically significant rise in NGAL was noted at 3 months (p=0.043) but no significant differences were noted for kidney injury molecule-1 (KIM-1), tumor necrosis factor, IL6, IL1β, white cell count, or C-reactive protein.
These are shown in Supplemental Tables 7 and 8 .
Reinterventions
Of the 27 AP group patients, 12 patients were reported with at least one device deficiency, 7 patients required reintervention due to device deficiency, 6 (22%) required system component replacement or repositioning and 3 (11%) required system explant as detailed in Table 4 . All fully recovered. No patients discontinued the study due to device deficiency. Of the 17 patients who completed the study, 11 did so without pump system reintervention although 2 required replacement chargers, and 7 of 10 patients who withdrew or died did so inspite of fully functioning pump system (although 1 required charger replacement and 2 required pump system explant due to pump pocket infection). Overall 66.6% of implanted systems functioned without reintervention until study completion, withdrawal or death.
Discussion
This study is the first randomized, controlled clinical trial that investigates the safety and efficacy of the alfapump system to treat RA compared with a control cohort managed with LVP. The data add to the existing body of evidence confirming that the alfapump system is efficacious in reducing, and in many cases eliminating, the need for paracentesis. This reduction was associated with significant improvements in HRQoL and nutrition. Although the total number of infectious complications was similar between groups, there were significantly more AKI events in the AP patients, the overall outcomes from which were not different between the groups.
The alfapump system is designed to obviate the need for paracentesis and successfully eliminated the need for LVP in more than 50% of implanted patients over 6 months. The majority of necessary LVPs were attributable to catheter blockage or migration and this remains an area of potential improvement in device design. Renal dysfunction, resulting in the decision to reduce the programmed rate of daily fluid transport in 2 patients, was also a contributing factor and may also be an area where device programming and peri-implant care protocols including albumin administration may be desirable.
Although there was no significant difference between groups in the number of AEs related to AKI and hyponatremia occurring >7 days after implantation, more of these events required hospitalization in the AP group. The underlying mechanism for this renal Nevertheless, it is important to note that patients with refractory ascites generally have high 6-month mortality. Furthermore, a number of these patients are expected to receive liver transplants. In this context, the number of patients who remained in the study and completed QoL questionnaires at the later study time points was limited, dampening the power of the study and statistical significance of QoL score improvements.
Implantation of the alfapump system was associated with improvements in nutritional status compared with the SoC group measured by improved BMI, hand grip, TSF and MMAC, compared with the LVP group. Due to the small number of patients evaluable at 6-months and the design of the sub-study, it remains unclear if these nutritional benefits extend for periods longer than 3-months. Additionally, the mechanism by which this nutritional benefit occurs is unknown but may involve attenuation of the increased resting energy expenditure associated with ascites [28].The improvements noted were similar to the improvements in body composition and resting energy expenditure seen following TIPS insertion [29, 30] .
Three pumps were explanted due to pump pocket issues such as infection or wound dehiscence. Clearly, wound infection or dehiscence limits the utility of the alfapump system and is problematic in patients with decompensated cirrhosis who are generally compromised with poor wound healing. Device deficiencies accounted for 7 reinterventions and no patients discontinued for this reason. This is an improvement compared to the results of the PIONEER study and may reflect the continual technological improvements to the alfapump system since commercialization in 2011.
Despite higher implantation cost for alfapump (£22,230), for the post-intervention cost, in AP group there was a trend towards stabilized costs, while in SoC group there was a steady increase mainly caused by high costs of paracentesis. Further improvements for the Alfapump in surgical protocols, post-implant care procedures, and system configuration e.g. catheter design, antibiotic coatings, and pump shape may help to reduce the cost for AP, and improve the cost-effectiveness of the alfapump. Further investigations with longer follow-up time are needed, to better understand the economic value of AP.
In conclusion, results of this study show that the alfapump system was effective in significantly reducing the need for paracentesis and improving HRQoL in those with refractory ascites due to cirrhosis and improved overall nutrition in a non-selected subset of those patients. Although SAEs were more common in the AP group these were generally limited and did not affect overall survival at 6 months. The impact of refinements in patient selection, patient care algorithms -including regular albumin administration to reduce the risk of circulatory dysfunction and infection -as well as modifications in device design remain areas for future study. Renal and urinary disorders  3  2  -1  ---Gastrointestinal disorders  2  1  1  ----Infections and infestations  13  12  ----1   Metabolism and nutrition disorders  2  -2  ----Hepatobiliary disorders  3  ---1  -2 Nervous system disorders 1 -
Counting is per event. FR = Fully recovered, RS = Recovered with sequelae, OI = Ongoing -Improved, OU = Ongoing -Unchanged, OW = Ongoing -Worsened, DI = Died. 
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Highlights
• alfapump reduces LVP requirement in patients with refractory ascities
• alfapump improves 6-month HRQoL compared to SoC in patients with refractory ascities
• sub-study alfapump patients showed nutrition cf. SoC in patients with ascities
